Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD

Adverum Biotechnologies Inc ADVM received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD). 

  • Adverum requested the FDA's feedback to align with the regulatory agency before filing the Investigational New Drug (IND) amendment for the Phase 2 trial. 
  • The trial is designed to evaluate the 2 X 10^11 vg/eye dose, a new, lower 6 X 10^10 vg/eye dose of ADVM-022, and new enhanced prophylactic steroid regimens, including new enhanced prophylactic steroid regimens, local steroids, and a combination of local and systemic steroids.
  • Related: Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD.
  • The company expects to complete the IND amendment process to enable the initiation of the Phase 2 trial of ADVM-022 in wet AMD in mid-2022.
  • Patient dosing in the trial to start in Q3 of 2022.
  • Price Action: ADVM shares closed 3.13% higher at $1.32 during after-hours trading on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!